Looking for a District of Columbia Singulair attorney? Get in touch with one of our District of Columbia Singulair attorneys now.
Home : Unsafe Drugs : Singulair : News Articles
Singulair - News Articles
-
Jul 1, 2008
Pharma Marketing, Italy -
maggio del 2000 per sviluppare e commercializzare una combinazione fissa di loratadina (Clarityn) di Schering-Plough e montelukast (Singulair) Merck. ... -
Jun 29, 2008
??????, South Korea -
?? ?????? ??? ????? ????? ‘????’(Claritin, loratadine)? ????? ‘????’(Singulair, montelukast) ???? ?? FDA ????? ... -
Jun 28, 2008
Business Spectator, Australia -
seeking to combine loratadine, the main ingredient in Schering's Claritin, and montelukast, the main ingredient in Merck's Singulair. ... -
Jul 21, 2008
Bloomberg -
By Michelle Fay Cortez and Shannon Pettypiece July 21 (Bloomberg) -- Merck & Co. and Schering-Plough Corp. fell in New York trading after their cholesterol drug Vytorin failed in a study to prevent complications from heart-valve disease and was linked to a higher rate ... -
Jul 21, 2008
CNNMoney.com -
Merck & Co. (MRK) posted a 5% increase in second-quarter net income, as the company pulled its 2008 and long-term guidance because of study results released earlier Monday that show Vytorin failed to show a benefit in people with a heart-valve problem. ... -
Jul 21, 2008
The Associated Press -
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and Nasdaq Stock Market: NYSE Merck & Co., ... -
Jul 21, 2008
MarketWatch -
By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Merck & Co. late Monday reported modestly higher second-quarter earnings on largely flat sales , helped in part by lower expenses and a favorable exchange rate. ... -
Jul 21, 2008
CNNMoney.com -
NEW YORK -(Dow Jones)- Schering-Plough Corp.'s (SGP) Chairman and Chief Executive Fred Hassan downplayed the results of a study that raised new questions ... -
Jul 21, 2008
Forbes, NY -
Financials led modest morning gains but bad news out of the pharmaceutical sector derailed stocks as US markets closed lower before a batch of post-bell earnings. The Dow finished the day down 0.3%, to 11,468, while the S&P 500 lost 0.1%, to ... -
Jul 21, 2008
Bizjournals.com, NC -
Shares of Schering-Plough Corp. fell nearly 12 percent Monday after the company's cholesterol drug Vytorin failed to prevent complications in heart patients and was linked to a higher rate of cancer in a study. Schering-Plough stock fell ...
-
Jul 21, 2008
Forbes, NY -
AP 07.21.08, 5:44 PM ET Drug developer Merck & Co. said Monday its second-quarter profit rose 5 percent as cost-cutting efforts more than offset a drop in sales of its asthma treatment Singulair and cholesterol drugs Zetia and Vytorin. The company and cholesterol drug ... -
Jul 21, 2008
Forbes, NY -
Beauty is in the eye of the beholder, and very few see either Merck or Schering-Plough's announcements on Monday as beautiful. Both pharma companies beat analyst estimates for their second-quarter earnings, but investors weren't satisfied with the beat of the Street after the disappointing ... -
Jul 21, 2008
CNNMoney.com -
By Peter Loftus Merck & Co.'s (MRK) report of improved second-quarter earnings was overshadowed Monday by a new study raising questions about its cholesterol drugs, while the quarterly numbers confirmed fears of a slowdown in sales of cervical-cancer vaccine Gardasil. ... -
Jul 21, 2008
Reuters -
NEW YORK, July 21 (Reuters) - Merck & Co Inc (MRK.N: Quote, Profile, Research) cut its sales outlook on two key medicines and said its long-termfinancial ... -
Jul 21, 2008
Reuters -
WASHINGTON, July 21 (Reuters) - US drug regulators said on Monday they are reviewing the latest data that found Schering-Plough Corp (SGP. N: Quote, Profile, Research) and Merck & Co Inc's (MRK.N: Quote, Profile, Research) drug Vytorin failed..."; ... -
Jul 21, 2008
MarketWatch -
By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Schering-Plough reported lower second-quarter earnings early Monday due largely acquisition costs associated with the 2007 buy of European biotech group Organon BioSciences. ... -
Jul 21, 2008
Bloomberg -
By Shannon Pettypiece Second-quarter net income rose to $1.77 billion, or 82 cents a share, the Whitehouse Station, New Jersey-based company said today in a ... -
Jul 21, 2008
Reuters -
By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - Merck & Co Inc (MRK.N: Quote, Profile, Research) cut its sales outlook on two key medicines on Monday and indicated its financial forecasts were in doubt after a mostly negative study of cholesterol treatment Vytorin, sending ... -
Jul 21, 2008
Los Angeles Times, CA -
Vytorin, the combination drug prescribed to lower cholesterol, sustained another blow Monday, when the author of a major clinical trial announced the ... -
Jul 21, 2008
Reuters -
By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) - The cholesterol fighter Vytorin sold by Merck & Co Inc (MRK.N: Quote, Profile, Research, Stock Buzz) and Schering-Plough Corp (SGP.N: Quote, Profile, Research, Stock Buzz) failed to..."; ...
Looking for a District of Columbia Singulair attorney? Get in touch with one of our District of Columbia Singulair attorneys now.
Pages: Previous ... 2 3 4 5 6 7 8 9 10 11 12 ... Next
